Ligand has assembled one of the largest portfolios of biopharmaceutical assets among our peers which provides investors the opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company.
| Partner | Program | Technology | Indication | Development Stage | ||||
|---|---|---|---|---|---|---|---|---|
| Pre-clinical/IND | Phase 1 | Phase 2 | Phase 3/NDA | Approved | ||||
| Acrotech/CASI | Evomela | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Alvogen | Voriconazole | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Amgen/Ono | Kyprolis | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Aytu Bioscience | Tuzistra | Vernalis Design Platform | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Aziyo | ECM portfolio | ECM | Med Device/Cardiology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Baxter | Nexterone | Captisol | Cardiovascular Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Biocad | Teberif | Selexis SUREtechnology | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Exelixis/Daiichi-Sankyo | Minnebro | Other/NCE | Metabolic Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Gilead | Veklury | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Hikma Pharmaceuticals | Voriconazole (EU) | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Lundbeck | Carnexiv | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Melinta | Baxdela | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Menarini | Frovatriptan | Vernalis Design Platform | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Merck | Noxafil IV | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Nanjing King-Friend | Voriconazole (China and US) | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Par Pharmaceuticals | Posaconazole-Par | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Pfizer | Duavee | Other/NCE | Women's Health |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Pfizer | VFEND | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Pfizer | Viviant/Conbriza | Other/NCE | Women's Health |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Sage | Zulresso | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Sedor | CE-Fosphenytoin | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Zydus | Bryxta and Zybev | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Zydus | Exemptia | Selexis SUREtechnology | Inflammatory Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Zydus | Rituximab | Selexis SUREtechnology | Inflammatory Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Zydus | Vivitra | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Zydus | Vortuxi | Selexis SUREtechnology | Inflammatory Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA Complete
|
Approved In Progress
|
| Aldeyra | Reproxalap | Captisol | Ophthalmology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Arcus | Zimberelimab (AB122) | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Aytu Bioscience | CCP-07/08 | Vernalis Design Platform | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Biocad | BCD-066 (Darbopoeitin) | Selexis SUREtechnology | Hematology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| CStone | CS1001 | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| IBC Generium | GNR-008 (Imiglugerase biosimilar) | Selexis SUREtechnology | Genetic Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Marinus | Ganaxolone-IV | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Medivis | CE-Opthalmology | Captisol | Ophthalmology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Outlook Therapeutics | ONS-3010 | Selexis SUREtechnology | Inflammatory Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Outlook Therapeutics | ONS-5010 | Selexis SUREtechnology | Ophthalmology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Palvella Therapeutics | PTX-022 | Other/NCE | To Be Determined |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Pharmascience | Voriconazole (Canada) | Captisol | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Sunshine Lake Pharma | Vilazodone | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Takeda | Pevonedistat (TAK-924) | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Travere Therapeutics | Sparsentan | Other/NCE | Metabolic Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Xi'an Xintong | Pradefovir | HepDirect | Infectious Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3/NDA In Progress
|
Approved Not Started
|
| Corvus | Ciforadenant and Atezolizumab | Vernalis Design Platform | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Corvus | Ciforadenant | Vernalis Design Platform | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Eisai | FYCOMPA (Perampanel) | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| GenMab | GEN1046 | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Gloria | Zimberelimab (GLS-010) | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Hanall Biopharma/Harbour BioMed | Batoclimab (HL161/HBM9161), (Korea/China) | OmniAb | Autoimmune |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Hanall Biopharma/Immunovant | Batoclimab (IMVT-1401) | OmniAb | Immunology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Janssen | Teclitasmab (JNJ-64007957) | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| J-Pharma | JPH203-SBECD | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Merck KGaA | M6620 | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Novartis | ECF843 (Lubricin) | Selexis SUREtechnology | Ophthalmology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Novartis | CE-Trametinib | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Opthea | OPT-302 | Selexis SUREtechnology | Ophthalmology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Precision Biologics | NEO-102 (Ensituximab) | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Sedor | CE-Budesonide | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Seelos | SLS-006 | Other/NCE | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Sermonix | Lasofoxifene | Other/NCE | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| VentiRx | Motolimod (VTX-2337) | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Verona | Ensifentrine | Vernalis Design Platform | Respiratory Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Viking | VK-0612 | Other/NCE | Metabolic Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Viking | VK-5211 | Other/NCE | Musculoskeletal Disorder |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Viking | VK-2809 | HepDirect | Metabolic Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| XTL | hCDR1 | Captisol | Inflammatory Disease |
Pre-clinical/IND Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Amgen | AMG-330 | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Aptevo | APVO436 | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Corvus | Ciforadenant | Vernalis Design Platform | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| CSL | CSL-324 | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Cuda | Cudafol | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| F-Star | FS-102 | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Gedeon Richter | Bevacizumab biosimilar | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Gedeon Richter | RGB-03 (Rituximab biosimilar) | Selexis SUREtechnology | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Genekey Biotech | Anti-PCSK-9 | OmniAb | Metabolic Disease |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Gossamer Bio | PFK-158 | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Janssen | JNJ-67371244 | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Janssen | JNJ-70218902 | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| MEI | ME-344 | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Merck KGaA | M6223 | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Meridian | ML-061 | Captisol | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Neuritek | NCO-48 Fumarate (NCO-1010) | LTP Platform | HBV |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Novartis | S55746 (BCL-201) | Vernalis Design Platform | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Novartis | MIK-665 (S64315) | Vernalis Design Platform | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Phoenix Tissue Repair | PTR-01 | Selexis SUREtechnology | Genetic Disease |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Proximagen | USL311 | Other/NCE | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Servier | S55746/S64315 | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
|
| Symphogen | SYM022 | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Symphogen | SYM023 | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Symphogen | SYM024 | OmniAb | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Takeda | TAK-925 | Captisol | Central Nervous System |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Vaxxas | Nanopatch | Captisol | To Be Determined |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| VentiRx | VTX-1463 | Captisol | Inflammatory Disease |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Viking | VK-0214 | Other/NCE | Genetic Disease |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
| Xi'an Xintong | MB07133 | HepDirect | Oncology |
Pre-clinical/IND Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3/NDA Not Started
|
Approved Not Started
|
Ligand’s partners currently have over 100 drug candidates in discovery/pre-clinical development or an IND has been filed
